Moreover, differential effects for acute vs. chronic treatment with CRF antagonists are suggested by findings of Mällo et al. (2004) who reported a reduction in anxiety (as defined by increased exploration) in an elevated-zero-plus-maze test following chronic, but not acute treatment with a selective CRF1-R antagonist. This evidence concerns the gene CRH and Anxiety.